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Abstract
Background: Faecal calprotectin (FC) is one of the most widely used non-invasive tests for the diagnosis and
assessment of Crohn’s disease (CD) activity. Despite this, factors other than disease activity which affect levels
have not been extensively reviewed. This is of importance when using FC in the diagnostic setting but also
may be of utility in studying the aetiology of disease.
Objectives: Our review outlines environmental risk factors that affect FC levels influencing diagnostic accuracy
and how these may be associated with risk of developing CD. FC as a surrogate marker could be used to
validate risk factors established in case control studies where prospective studies are not feasible. Proof of this
concept is provided by our identification of obesity as being associated with elevated FC, our subsequent
confirmation of obesity as risk factor for CD and the subsequent verification in prospective studies, as well as
associations of lack of physical activity and dietary fibre intake with elevated FC levels and their subsequent
confirmation as risk factors in prospective studies.
Conclusion: We believe that FC is likely to prove a useful surrogate marker for risk of developing CD. This
review has given a theoretical basis for considering the epidemiological determinants of CD which to date
has been missing.
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Background
Faecal calprotectin (FC) is one of the most widely used
non-invasive tests for the diagnosis and assessment of
Crohn’s disease (CD) activity. Despite this, factors other
than the presence of disease and disease activity that
affect levels, have not been adequately reviewed. This is
important particularly in the context of the use of FC in
assessing the risk that a patient with symptoms may
have disease.
Another potentially important issue is the question as
to whether FC levels may be of use in establishing a
subject’s risk of developing Crohn’s disease in the future.
This possibility will also be further elaborated on in this
review, as factors influencing levels in asymptomatic
subjects may also have a bearing on this.
CD is a complex chronic disease. Over the last decade
large population studies and experimental studies have
helped to elucidate the aetiopathogenesis of the disease.
The onset of CD is caused by an interaction of genetic
susceptibility, environmental triggers and subsequent
change in the intestinal microbiome causing disruption
of the host immunity [1]. As with many other diseases,
the relative contribution of environment over genetic
influences increases with age. With early onset CD,
genetics are likely to play an important role, whereas in
later onset disease the effect of the environment is likely
to be more prominent.
Studies of environment as a risk factor for disease
are more difficult than genetic studies, particularly for
relatively uncommon disorders such as CD where case
control studies are the principle tools of investigation.
Case control studies are prone to many types of bias,
such as: recall bias, missing data, selection bias and
temporal bias [2].
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More reliable prospective cohort studies have a number
of weaknesses: they require large numbers of subjects to be
followed for long periods of time entailing a high economic
cost. The induction period between risk factors and onset
of disease is not yet known, making prospective follow up
lengthy. Detailed information about exposure is not pos-
sible to get retrospectively, and importantly, prospective
studies across the whole age range of CD presentation are
not readily available.
What is needed is a surrogate marker for risk of
developing CD. Surrogate markers have been widely
used in the more prevalent cardiovascular diseases
such as blood lipids and inflammatory markers. They
allow detailed study of environmental exposures and
more rapid hypothesis generation, avoiding the pit
falls or complementing case control studies and
compensating for the limitations of prospective cohort
studies. Importantly they allow the study of interven-
tions designed to mitigate risk. A good example in CD
would be with the effect of detailed dietary compo-
nents as commented upon recently by Kaplan GG,
where it would be useful to be able to study the role of
different types of fibre on risk of developing CD [3].
Additionally, a surrogate marker could be used to
validate risk factors established in case control studies
where prospective studies are not feasible.
FC maybe a useful surrogate marker of developing CD as
suggested by family studies. These have shown increased
lifetime risk of developing CD in children whose parents
have CD than the general population [4]. Additionally non-
affected family members who are known to be at increased
risk, have consistently shown to have increased levels of
FC; 49 % of relatives but only 13 % of spouses (who did not
actually have CD) [5]. 5-10 % of first degree relatives will go
on to develop CD [6]. Additionally, elevated FC is a well
validated marker of risk of relapse in established CD in
remission, which whilst is a different situation to risk of
developing disease is likely to share some aetiological
factors in common such as cigarette smoking [7, 8].
The remainder of this review explores the environ-
mental factors which affect FC levels in subjects without
disease and argues that as well as being an excellent
marker of disease activity and relapse risk, may also be a
candidate surrogate marker of risk of developing CD in
subjects yet to develop the disease. We will make this
argument by demonstrating that many environmental
exposures associated with elevated FC in healthy
subjects are themselves risk factors for CD. We will
begin by assessing what is known about the determi-
nants of FC levels in healthy subjects.
Faecal calprotectin
Calprotectin is a 36 kDa Calcium and zinc binding protein
expressed by neutrophils. FC concentration is raised due to
neutrophil aggregation in the mucosa on inflamed intestine;
it is therefore useful as a non-invasive marker for inflamma-
tion of inflammatory bowel disease (IBD). Levels correlate
well with Indium white cell scanning and also gut perme-
ability measured by other means [9]. There has been a great
deal of interest in gut permeability in the aetiology of CD
both in experimental and clinical studies and many of the
findings with gut permeability are being replicated with FC
[10–12]. The measurement of gut permeability itself how-
ever is cumbersome and not well suited to large-scale
studies. Additionally, it is likely that gut permeability is
merely a measure of gut mucosal inflammation, which
is more related to the pathogenesis of CD. FC testing
is non-invasive, stable, simple, easy to perform, rapid
and reproducible. Importantly it is highly specific for
intestinal inflammation. Other factors that affect
levels will be reviewed shortly.
FC is now a well-established surrogate marker for
diagnosing the onset of inflammatory bowel disease [13].
In the United Kingdom, National Institute of Clinical
Excellence guidelines recommend its use to differentiate
between functional gut disorders and a pathological
organic cause of disease. It is also a useful in monitoring
therapeutic management, prognosis and detecting
relapse [14–17]. Although the sensitivity of FC in detect-
ing intestinal inflammation is consistently high, in adults
in developed world populations the specificity is only in
the order of 80 % [13, 18]. Hence in a population with a
relatively low prevalence of IBD diagnostic accuracy is
relatively poor.
Levels are also elevated in other diseases such as gastro-
enteritis, gastrointestinal malignancies, reflux disease, cystic
fibrosis and diverticulitis [13]. Despite this, little is known
about the determinants of levels in normal subjects, and
whether sensitivity and specificity vary with the age of the
subject being tested.
Environmental factors and faecal calprotectin
In a middle-aged healthy general population sample of
300 subjects (50-70 years old) our group has previously
demonstrated that FC levels are independently elevated
in association with environmental exposures such as low
fibre intake, lack of physical exercise and increasing age
[19]. The consumption of fibre and specifically vegetable
fibre was found to have an inverse relationship with FC
levels. There was a significant difference in the geomet-
ric mean FC (μg/g) between the lowest fibre quartile
(which consumed < 9.8 % fibre versus the highest fibre
quartile group (which consumed 17 to 38.8 % fibre).
There was a 31 % increase in FC per decade increase in
age, a 40 % increase per increase in body mass index
(BMI) by 10 kg/m2, a 31 % decrease in those who exer-
cised regularly, and a 2 % decrease for each percentage
increase in proportion of the diet that was fibre
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consumption. All ofbody mass index these changes were
significant after mutual adjustment. Trends were seen in
cigarette consumption with a 7 % increase per pack year
of smoking and a trend with vegetable intake with a
10 % decrease per daily portions consumed. There was
no relation to proportion of the diet consumed as fruit
or fat. There was a suggestion of U shaped relation with
BMI. The lowest quartile (BMI 17.6 to 23.5) had a
geometric mean FC level of 30 μg/g; the second quartile
(BMI 23.6 to 25.6) mean FC of approximately 26 μg/g;
the third quartile (BMI 25.7-28.1) had a mean FC of
approximately 30 μg/g and the highest BMI quartile
(BMI 28.2-41.2) had an FC of approximately 40 μg/g.
Even without allowing for the likely u shaped relation-
ship there was a significant positive association with
BMI as a continuous variable. Also from the same
cohort proton pump inhibitor (PPI) usage was found to
be associated with elevated levels (geometric mean 78.16
ug/g vs. 30.9 ug/g p < 0.0001) [20].
For a test that is being widely used, it is surprising that so
little work has been done on the determinants of normal
levels. No other group has looked at the associations with
exercise and fibre or other dietary components but a few
small studies have assessed the association of FC with
obesity with mixed results.
A small study of 13 obese adult subjects did not find
confirmation of an association with FC, whereas a study
34 children with severe obesity did [21, 22]. Another
small study again in adolescents showed only a small
difference in FC between obese and normal subjects, but
the obese subjects were significantly younger than the
normal weight subjects and the children were not
severely obese [23]. Finally a study in 28 adults with a
range of weights demonstrated detectable FC only in
obese subjects with an obese pattern of microbiota [24].
In a recent interventional study exploring the effect of
weight loss in a community population, FC levels were
found to fall with weight loss only in those with elevated
levels at baseline [23]. Again, this was a small study.
These small experimental studies provide partial
support to our observation in the only large study to
date on the determinants of FC, though larger confirma-
tory studies are still required.
Possible mechanisms for associations of FC with
environmental factors
Low fibre intake is also associated with elevated circu-
lating inflammatory markers [25]. The mechanism
could be through alterations in bowel flora or nutrient
density [26, 27]. The reduction with physical activity we
postulated could be through the enhanced vagal tone
that goes with physical fitness. The vagus nerve is
known to have anti-inflammatory effects on the gut or
reduced sympathetic tone that goes with increased
vagal tone could again result in reduced inflammation
[28]. There are also reports that exercise can alter
bowel flora [29, 30].
Elevated BMI, which has been shown to be associated
with increased gut permeability in both animal and
human studies could be associated through a variety of
mechanisms, including altered bowel flora, the effects of
circulating inflammatory cells and markers or through
direct effects of dietary fats on local cytokine production
[30, 31]. Supporting the idea that altered bowel flora in
the obese could mediate obesity associated elevations on
FC, is a study in subjects with a variety of BMIs. This
showed there was a distinct obesity related microbial
profile and that it was this profile that was associated
with elevated FC. Specifically in the obese microbiota
profile there was reduced bacterial diversity, a decreased
Bacteroides to Firmicutes ratio and an increased
abundance of proinflammatory Proteobacteria [24].
Environmental risk factors and Crohns disease
There are two distinct groups of risk factors for developing
CD; those relating to the adult environment likely to be
important in later onset CD and those relating to the early
childhood environment likely to be of more relevance to
early onset disease [32, 33]. There is little known about the
determinants of FC in normal children and hence this re-
view will not address risk factors in this age group further.
Faecal Calprotectin as a surrogate marker for risk of
developing Crohns disease
The evidence that FC may be a useful surrogate
marker for risk of developing CD will now be reviewed
by examining the evidence that exposures associated
with changes in FC are similarly associated with
altered risk of devloping CD. More recently powerful
evidence from prospective cohort studies is emerging
on the role of the environment in risk of developing
CD, clarifying much of the earlier contradictory
evidence about environment [34–40].
We will start by evaluating the evidence that abdominal
obesity may be risk factor for developing CD. This
hypothesis has been suggested by our original observation,
that FC increases with increasing BMI in middle-aged
healthy adults. This is a powerful example of the potential
for utilizing FC as a marker of risk of developing CD
as the association between CD and high BMI seems
counterintuitive.
Obesity
Obesity has been described as a global pandemic and is
now a high priority action point in public health [41].
The first evidence that obesity may be a risk factor for
developing CD came from our case control study of 524
patients [42]. This demonstrated a U shaped relationship
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between BMI at diagnosis and CD risk development;
participants with CD were more likely to present with
extremely low or extremely high BMI compared to
subjects with ulcerative colitis (UC). Furthermore most
of the obese subjects were in the older age group. There
was a graded dose response of risk, with risk being
highest in the most obese [38].
This evidence has been consolidated in a prospective
study of the Danish National Birth Cohort of 75,008
women with 138 incident cases of CD, which found a U
shaped dose-response relationship between BMI and risk
of CD development, which was highest in those of low
BMI and very high BMI [43]. There was median follow-up
of 11 years and median age at start of follow-up was
30.2 years (27.2-33). Therefore it would be too premature
to observe Montreal classification A3 disease (>40 yrs age
at disease onset) in this cohort [44]. Further follow up
studies would be interesting to examine CD in the older
population or A3 group.
Recent confirmation of an association between obesity
and CD has come from The Nurse’s Health Study (NHS)
[40]. This is one of the largest and longest running
prospective cohort studies. Starting in 1976 recruiting
married nurses aged 30-55 (NHS 1) and was then
expanding in 1989 recruiting women aged 25 to 42 years
(NHS 2), a cohort of 238,000 nurse participants in the
United States [39]. A cofounding factor however is that
the recruitment was restricted to white female nurses
who are likely to be highly motivated and health
conscious thus not demonstrating the same degree of
risk as a general population.
In the nurse cohort study among 115,374 United
States women (median age 35 years), 144 cases of CD
were identified. It was found that increased adiposity as
measured by high BMI, waist-hip ratio and body shapes
has increased incidence of CD [34]. The authors col-
lected baseline information on anthropometrics, includ-
ing: height, weight, waist and hip circumference, weight
at age 18, and body shape at age 20 (using a 9 level
pictogram from lean to most overweight). Using a cox
proportional hazard model, hazard ratios for CD were
calculated adjusting for age, smoking, physical activity,
history of appendicectomy, latitude of residence, use of
oral contraceptive pill, postmenopausal status and use of
Non-Steroidal Anti-inflammatory Drugs (NSAIDS). The
median time from enrolment to diagnosis was 9.7 years
for CD. It was found that the highest BMI quartile
(BMI > 30) had increased risk of CD multivariate
adjusted HR 1.77 (95 % CI 1.16-2.70). Additionally, it
was found that there was an association between body
shape at age 20 and risk of CD, with a MV-adjusted HR
of CD of 1.77 (95 % CI, 1.15-2.71) for women with
overweight and obese body shape, compared to women
with a thin or slender body shape [37, 40].
However, a recent cohort study of 300,724 participants
found with a much smaller number of incident cases, that
obesity/high BMI was not associated with the risk of
development of CD [38]. Participants were men and
women aged 20 to 80 years from 10 European countries
without CD or UC. Recruitment took place from 1991 to
1998 and participants were followed up until 2004.
Median age of CD diagnosis was 56.4 (range 24 to
78.7 years), much older than the previous two confirma-
tory studies with median time after recruitment of
5.1 years (range 1.5 years to 14 years) However the
incident cases of CD in this study was 75 which is fewer
than NHS 2 which had a total of 144 incident cases [40].
In addition the length of follow up is also comparatively
shorter. It may be possible therefore that a true risk was
not detected due to small number of the incident cases,
and the different age range of cases meant that a different
spectrum of Montreal sub-types was being studied.
Diet
A recent systematic review of dietary factors on risk of
developing and risk of relapse in IBD concluded that no
firm conclusions could be drawn [45]. The authors identi-
fied 24 case-control studies which examined the intake of
specific food components and CD onset. Nineteen studies
reported the consumption of fruit and vegetables of which
5 studies found a significant protective effect of high
overall fruit intake for the onset of CD. Six further studies
found a protective effect of pre-illness high vegetable
intake. Furthermore, high intake of grain-derived products
was consistently shown to be negatively associated with
development of CD in five studies; the authors suggested
that this implied the protective role of a high fibre intake.
Several studies found increased risk of CD development
from high intake of carbohydrates (sugar, sugar
containing foods, monosaccharides, disaccharides and
starch). However the NHS I and II, did not find any
association with long-term intake of total fat, satu-
rated fats or unsaturated fats with risk of CD [16, 34].
As previously mentioned, from our study on the deter-
minants of FC, from diet, only fibre intake would be
predicted to be a risk factor for CD [20].
Shedding light on this matter is a recent report of
findings from the American Nurses study, which has
demonstrated that reduced fibre intake is indeed a risk
factor for late onset CD [35]. This is supported by our
own findings about the association of fibre intake with
FC. Using data of 170,776 women, followed up over
26 years with a median age of CD diagnosis of 52 years,
the authors found that the highest quintile of fibre
intake (median 6.4 g/day) was associated with a lower
incidence of CD. The high fibre group were more
likely never to have smoked, less likely to be obese
and less likely to use aspirin. This supports data from
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previous case-control studies that have found low
consumption of fibre and high consumption of sugar
to be significantly associated with the development of
CD [46]. No association was found between fibre and
risk of ulcerative colitis. Other components of diet
that have been implicated in the past were not shown
to be associated with the development of CD [47]. In
the same cohort no association was found between
consumption of fat and specific fatty acids [36]. This
mirrors our findings on the effect of different dietary
components on FC.
This recently reported study adds further support to
the concept that FC is a useful surrogate marker for
risk of CD development. In particular it opens the
door to more detailed dietary investigation into the
aetiology of CD.
Physical inactivity
Like diet, physical activity as a risk factor for CD
development in case control studies is highly prone to
bias. In an early retrospective study, it was found that
occupations involving outdoor work and physical activity
(including brick laying and construction workers) con-
ferred a protection against onset of IBD, whilst people in
occupations associated with lower physical activity such a
desk work were at greater risk of developing IBD [48]. A
larger Danish retrospective cohort study looked at occu-
pation and risk of hospitalisation with IBD. Comprising of
2 cohorts of over 2 million people it was found that people
with sedentary work had a standardized hospitalisation
ratio of 125 (95 % CI 116.9 – 133.1) [49]. Sedentary work
was interpreted as lack of physical activity.
A small case-control study (n = 305) found that
regular physical activity 5 years before disease onset
was associated with a decreased risk ratio. Daily exer-
cise in men conferred a statistically significant RR 0.4
(0.2-0.9). Daily exercise in women was found to have a
lower risk of CD, though this was not significant [50].
This was further supported by a study that found in
pre-illness IBD patients (n = 88) reports of physical
activity was lower compared to clinical controls (n =
68) [51]. These studies however experience biases
affecting most case-control studies.
The data from the above studies are strengthened by
recent data from the American NHS which demon-
strated the protective effects of physical activity [39].
The authors divided physical activity level into quintiles
and found that those in highest physical activity group
were at a reduced risk of developing CD compared to
the lowest physical activity quintile HR 0.64 (0.44 to
0.94), after adjusting for confounders such as: body mass
index, smoking, appendicectomy, oral contraceptives,
NSAIDs, and postmenopausal hormone therapy.
Smoking
Smoking is one of the first established risk factors for the
development of CD [52]. The association has been con-
firmed repeatedly in numerous studies and has been
evaluated by systematic review and meta-analysis showing
smoking to confer a significant higher risk of development
of CD [53]. We identified a weak but non-statistically
significant trend between smoking and FC levels [19].
Non-steroidal anti-inflammatory drugs
Regular use of NSAIDs has been associated with the risk
of developing CD. The EPIC cohort found that regular
aspirin use increased the risk of developing CD by 6 fold
(OR = 6.14, 95 % CI = 1.76–21.35) [38].
There is also further prospective cohort data from the
NHS which showed that high frequency and long
duration of NSAID use, though not including aspirin,
was associated with higher risk of CD occurrence [34].
Proton pump inhibitors
The role of PPIs on the risk and effect on disease course
of CD remains controversial. To date there is no pro-
spective data on CD risk. Juillerat and colleagues found
the PPI group to have increased relative risk of experien-
cing a mild flare compared to the non-PPI group;
adjusted RR 1.18 (1.02 -1.37) [54]. More recently, it has
been demonstrated in a retrospective case-control study
that CD patients using PPIs were at significantly
increased risk of developing severe flare-up compared to
the CD PPI naïve group (OR 6.8 95 % CI 1.1 – 42.85)
and also at significant risk of developing mild flare-up
(OR 14 95 % CI 3.377-63.62) [55].
Conclusion
The specificity of FC for detecting IBD could be
improved by considering factors that affect levels in
normal subjects. Specifically, some form of adjustment
for age needs to be considered together with a history of
proton pump inhibitor use.
We believe that FC is likely to prove a useful surrogate
marker for risk of developing CD. It will help in exploring
environmental determinants of CD, particularly diet. This
review has also given a theoretical basis for considering the
epidemiological determinants of CD which to date has been
missing. We believe that an important part of validation of
novel environmental risk factors for CD perhaps established
in case control studies, should be that they have the appro-
priate effect on FC. It is often difficult, impossible or expen-
sive to obtain long-term prospective data, particularly in
young subjects. We believe that this concept has been
validated by our identification of the association of BMI
with FC, subsequent case-control confirmation and more
recent confirmation in prospective cohort studies.
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Further large-scale studies are called for to better
characterize the determinants of FC. This may not only
be important for CD but also possibly for understanding
a variety of cardio-metabolic disorders as the effects of
the gut microbiome on FC, metabolic and systemic
inflammatory activity become better understood.
The utility of a surrogate marker for development of
CD risk would be of enormous benefit. This is illustrated
by the contradictory results of studies of diet and other
environmental agents into the pathogenesis of disease
onset. Previously gut permeability has been considered
as a possible surrogate marker, but the difficulty in its
measurement has precluded large-scale studies.
A small number of recent prospective studies support the
potential utility of FC as a surrogate marker of development
of CD risk. FC has also proved its utility in the discovery of
a novel and unexpected risk factor for CD; namely, obesity.
Large-scale population based studies are called for to
investigate the determinants of FC in otherwise healthy
subjects for a number of reasons. Not least, a better
understanding of the determinants of normal levels will
improve the specificity of the test. This is important, as
the end result of a positive FC, is a colonoscopy; an
invasive and expensive test. Secondly, there are no other
better candidates as a surrogate marker for risk of CD
development and it will provide a better understanding
of the pathogenesis of CD. If the findings from our
original population based study are replicated, then
Abbreviationsfuture candidate risk factors can be
assessed for their plausibility not only through case-
control studies, with their inherent unreliability but also
through their effects on FC.
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